The National Institute for Health and Care Excellence (NICE) has rejected proposals to combine immunotherapy and chemotherapy for some adults with small cell lung cancer.
It’s thought that combining the immunotherapy drug atezolizumab (Tecentriq) with standard chemotherapy medication could give patients more time before their cancer spreads, thereby improving survival rates. But NICE concluded that there wasn’t enough evidence to suggest these benefits were sustained, rendering the treatment cost-prohibitive.
Please register or login to comment!
Register now Login